Cargando…

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples

BACKGROUND: The Estrogen Receptor alpha (ERα) is the key transcriptional regulator in luminal breast cancer and is therefore the main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by the transcriptional capacities of ERα, which are a direct consequence of the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zwart, Wilbert, Koornstra, Rutger, Wesseling, Jelle, Rutgers, Emiel, Linn, Sabine, Carroll, Jason S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637562/
https://www.ncbi.nlm.nih.gov/pubmed/23565824
http://dx.doi.org/10.1186/1471-2164-14-232
_version_ 1782267501470547968
author Zwart, Wilbert
Koornstra, Rutger
Wesseling, Jelle
Rutgers, Emiel
Linn, Sabine
Carroll, Jason S
author_facet Zwart, Wilbert
Koornstra, Rutger
Wesseling, Jelle
Rutgers, Emiel
Linn, Sabine
Carroll, Jason S
author_sort Zwart, Wilbert
collection PubMed
description BACKGROUND: The Estrogen Receptor alpha (ERα) is the key transcriptional regulator in luminal breast cancer and is therefore the main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by the transcriptional capacities of ERα, which are a direct consequence of the receptors binding preference at specific sites on the chromatin. The identification of ERα binding signatures on a genome-wide level has greatly enhanced our understanding of Estrogen Receptor biology in cell lines and tumours, but the technique has its limitations with respect to its applicability in limited amounts of tumour tissue. RESULTS: Here, we present a refinement of the ChIP-seq procedures to enable transcription factor mapping on limited amounts of tissue culture cells as well as from a limited amount of tumor tissue derived from core needle biopsies. Our approach uses a carrier that can be removed prior to DNA amplification and sequencing. CONCLUSION: We illustrate the applicability of this refined technology by mapping the ERα genome-wide chromatin binding landscape in core needle biopsy material from primary breast tumours. With this, our refined technology permits for a high-resolution transcription factor mapping even from clinical samples.
format Online
Article
Text
id pubmed-3637562
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36375622013-04-28 A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples Zwart, Wilbert Koornstra, Rutger Wesseling, Jelle Rutgers, Emiel Linn, Sabine Carroll, Jason S BMC Genomics Methodology Article BACKGROUND: The Estrogen Receptor alpha (ERα) is the key transcriptional regulator in luminal breast cancer and is therefore the main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by the transcriptional capacities of ERα, which are a direct consequence of the receptors binding preference at specific sites on the chromatin. The identification of ERα binding signatures on a genome-wide level has greatly enhanced our understanding of Estrogen Receptor biology in cell lines and tumours, but the technique has its limitations with respect to its applicability in limited amounts of tumour tissue. RESULTS: Here, we present a refinement of the ChIP-seq procedures to enable transcription factor mapping on limited amounts of tissue culture cells as well as from a limited amount of tumor tissue derived from core needle biopsies. Our approach uses a carrier that can be removed prior to DNA amplification and sequencing. CONCLUSION: We illustrate the applicability of this refined technology by mapping the ERα genome-wide chromatin binding landscape in core needle biopsy material from primary breast tumours. With this, our refined technology permits for a high-resolution transcription factor mapping even from clinical samples. BioMed Central 2013-04-08 /pmc/articles/PMC3637562/ /pubmed/23565824 http://dx.doi.org/10.1186/1471-2164-14-232 Text en Copyright © 2013 Zwart et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methodology Article
Zwart, Wilbert
Koornstra, Rutger
Wesseling, Jelle
Rutgers, Emiel
Linn, Sabine
Carroll, Jason S
A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
title A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
title_full A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
title_fullStr A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
title_full_unstemmed A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
title_short A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
title_sort carrier-assisted chip-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637562/
https://www.ncbi.nlm.nih.gov/pubmed/23565824
http://dx.doi.org/10.1186/1471-2164-14-232
work_keys_str_mv AT zwartwilbert acarrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT koornstrarutger acarrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT wesselingjelle acarrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT rutgersemiel acarrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT linnsabine acarrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT carrolljasons acarrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT zwartwilbert carrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT koornstrarutger carrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT wesselingjelle carrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT rutgersemiel carrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT linnsabine carrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples
AT carrolljasons carrierassistedchipseqmethodforestrogenreceptorchromatininteractionsfrombreastcancercoreneedlebiopsysamples